MYMD Profile
MyMD Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutic solutions aimed at addressing the underlying causes of various diseases. The company's primary focus is on developing MYMD-1, a cutting-edge drug platform featuring a clinical-stage small molecule designed to modulate the immune system. MYMD-1 targets tumor necrosis factor-alpha (TNF-a) and other pro-inflammatory cytokines implicated in chronic inflammation. This therapeutic approach is intended to delay the aging process, enhance longevity, and provide treatment options for autoimmune diseases and COVID-19-associated depression.
Additionally, MyMD Pharmaceuticals is advancing Supera-CBD, a synthetic derivative of cannabidiol. This product is under development for the management of chronic pain, addiction, and epilepsy. Supera-CBD aims to offer a novel approach to these conditions, leveraging the therapeutic potential of cannabinoids while avoiding some of the limitations associated with traditional treatments.
The company's robust pipeline reflects its commitment to addressing significant unmet medical needs through targeted therapeutic interventions. MyMD Pharmaceuticals employs a science-driven approach, supported by clinical research and development, to create transformative therapies that can improve patient outcomes and quality of life.
Founded in 2014 and headquartered in Baltimore, Maryland, MyMD Pharmaceuticals combines cutting-edge scientific research with a strategic focus on developing next-generation treatments. Its dedication to advancing innovative therapies positions the company at the forefront of pharmaceutical research, with the potential to make substantial contributions to the fields of immunology, aging, and cannabinoid-based medicine.
|
